NewAmsterdam Pharma Company N.V. (NAMS)

Market Cap	3.79B +46.3%
Revenue (ttm)	22.50M -50.6%
Net Income	-203.82M
EPS	-1.72
Shares Out	114.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	725,189
Open	31.65
Previous Close	32.81
Day's Range	31.61 - 33.23
52-Week Range	14.06 - 42.00
Beta	0.13
Analysts	Strong Buy
Price Target	46.75 (+41.71%)
Earnings Date	May 7, 2026

About NAMS

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartere...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: NAMS
• Website: https://www.newamsterdampharma.com

Financial Performance

In 2025, NAMS's revenue was $22.50 million, a decrease of -50.61% compared to the previous year's $45.56 million. Losses were -$203.82 million, -15.64% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for NAMS stock is "Strong Buy." The 12-month stock price target is $46.75, which is an increase of 41.71% from the latest price.

Price Target

$46.75

(41.71% upside)

Analyst Consensus: Strong Buy